Pure Red Cell Aplasia Following Neoadjuvant Docetaxel/Carboplatin/Trastuzumab (TCbH) in a 45‑Year‑Old Woman With Breast Cancer Successfully Treated With Cyclosporine
American Journal of Case Reports · 2026
DOI: 10.12659/ajcr.952933 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Case Reports, 2026. Verfasst von Yuanyuan Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Breast Department, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Cyclosporine, Red-Cell Aplasia, Pure, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is commonly treated with docetaxel/carboplatin/trastuzumab (TCbH). While anemia is a common complication, progression to pure red cell aplasia (PRCA) is extremely rare. This report presents the case of a 45-year-old woman with right breast ductal carcinoma (cT3N2M0, HER2-positive) who developed PRCA following neoadjuvant TCbH and was effectively treated with cyclosporine. CASE REPORT A 45-year-old woman with right breast invasive ductal carcinoma (cT3N2M0, HER2-positive) received neoadjuvant TCbH. After the sixth cycle, she developed progressive anemia refractory to erythropoietin, with hemoglobin (Hb) decreasing to 34.2 g/L. After transfusion, she underwent modified radical mastectomy with pathological complete response. Postoperatively, anemia worsened with marked reticulocytopenia (reticulocytes 3.8×10⁹/L; 0.2%). Bone marrow examination revealed markedly reduced erythroid precursors. Acquired PRCA was diagnosed after excluding iron deficiency, megaloblastic anemia, hemolytic anemia, hematologic malignancies, autoimmune disorders, aplastic anemia, thymoma, and infections. Oral cyclosporine (100 mg twice daily) induced complete hematologic remission at 7 weeks and was tapered over 2 years. During the adjuvant trastuzumab/pertuzumab (HP) treatment, Hb remained ≥110 g/L. A heterozygous germline BRCA1 mutation (c.788delG) was identified. At the 4.5-year follow-up, there is no recurrence of either breast cancer or anemia. CONCLUSIONS This case highlights PRCA as a severe complication of TCbH therapy. Reticulocytopenia with refractory anemia warrants timely bone marrow examination. In this patient, cyclosporine was effective; after anemia correction, HP was tolerated. The observed gBRCA1 mutation is a hypothesis-generating finding requiring further validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Breast Department, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China.
- Department of Medical Imaging, Suzhou Kowloon Hospital, School of Medicine, Shanghai Jiao Tong University, Suzhou, Jiangsu, China.
- Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Breast Department, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong Universit, Shanghai, China.
Zitieren
APA
Chen, Y., Chen, F., Luo, R., & Ye, X. (2026). Pure Red Cell Aplasia Following Neoadjuvant Docetaxel/Carboplatin/Trastuzumab (TCbH) in a 45‑Year‑Old Woman With Breast Cancer Successfully Treated With Cyclosporine. American Journal of Case Reports. https://doi.org/10.12659/ajcr.952933
Vancouver
Chen Y, Chen F, Luo R, Ye X. Pure Red Cell Aplasia Following Neoadjuvant Docetaxel/Carboplatin/Trastuzumab (TCbH) in a 45‑Year‑Old Woman With Breast Cancer Successfully Treated With Cyclosporine. American Journal of Case Reports. 2026. doi:10.12659/ajcr.952933
BibTeX
@article{Chen2026,
author = {Chen, Yuanyuan and Chen, Fang and Luo, Rongkui and Ye, Xin},
title = {Pure Red Cell Aplasia Following Neoadjuvant Docetaxel/Carboplatin/Trastuzumab (TCbH) in a 45‑Year‑Old Woman With Breast Cancer Successfully Treated With Cyclosporine},
journal = {American Journal of Case Reports},
year = {2026},
doi = {10.12659/ajcr.952933}
}
EUVIMED